Q-omics provides the consensus-scored UBTFL7 profile across patient tissues and cancer cell-line models. UBTFL7 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, UBTFL7 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, UBTFL7 RNA expression shows 7,751 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, THCA, and TGCT as cancer lineages where UBTFL7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBTFL7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBTFL7 survival associations across molecular data types. UBTFL7 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBTFL7 RNA expression–survival associations across cancer types. High UBTFL7 expression shows unfavorable associations in LIHC, SKCM, THCA, ACC, BRCA and THYM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for UBTFL7 RNA expression.
This table summarizes UBTFL7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for UBTFL7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBTFL7 shows lower tumor expression in THCA and higher tumor expression in LUAD. The THCA box plot shows higher UBTFL7 RNA expression in normal versus tumor tissue (log2 FC = −0.029, t-test p = .039).
This table shows molecular features associated with UBTFL7 in patient tissues and cancer cell lines. In patient samples, UBTFL7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
